Eugenol, a potential schistosomicidal agent with anti-inflammatory and antifibrotic effects against Schistosoma mansoni, induced liver pathology [Corrigendum]
El-kady AM, Ahmad AA, Hassan TM, et al. Infect Drug Resist. 2019;12:709–719.
On page 709 in the abstract, in the Materials and methods section should read “The murine model of S. mansoni was established in four groups of adult male Balb-c mice; group I (infected non-treated group), groups II and III (infected groups) treated orally with eugenol and praziquantel
(PZQ), respectively and group IV (non-infected non treated group). The expression of the sensitive immunohistochemical marker α-smooth muscle actin (α-SMA) in schistosome-infected tissues was determined. In addition, parasitological, biochemical, and histological parameters that reflect disease severity and morbidity were examined.”
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]